MPO and TRH within leukemia stem cells increased chemosensitivity in acute myeloid leukemia

The "7+3" regimen is widely recognized as the established standard induction therapy for newly diagnosed acute myeloid leukemia (AML), exhibiting a complete remission (CR) rate of 70%. By employing single-cell RNA sequencing (scRNA-seq), we meticulously examined the cellular states of bone marrow mononuclear cells from AML patients at the time of diagnosis and identified leukemia stem cells (LSCs) among these cells. The genetic profiles of the LSCs were subsequently compared between the CR and non-CR groups and further validated using independent cohorts. The non-CR AML patients exhibited a significant increase in the proportion of immature cells during hematopoiesis within the AML cell populations. Moreover, we found that expressions of MPO (log2 fold-change = 0.89; adjusted p <0.0001) and TRH (log2 fold-change = 0.65; adjusted p <0.0001) within LSCs were significantly higher in the CR than non-CR groups, which were further validated by independent cohorts. Furthermore, patients with higher expression of TRH and MPO demonstrated substantially improved relapse-free survival (p = 0.009 for TRH; p = 0.002 for MPO) and overall survival (p < 0.001 for TRH; p = 0.002 for MPO). The dysregulation of the OXPHOS pathway, along with altered interferon alpha and gamma responses, disrupted cholesterol homeostasis, and aberrant MYC activity, may contribute as underlying mechanisms for the observed association between MPO or TRH and chemotherapy response. The bone marrow samples were collected from 20 consecutive de novo AML patients who underwent "7+3" or "7+3"-like induction therapy. These patients were categorized into two groups based on their bone marrow status assessed approximately 28 days after the induction chemotherapy: complete remission (CR) group (n = 15) and non-complete remission (non-CR) group (n = 5). Clinical features of the patients were provided in Supplemental Table 1 in our manuscript. The processed data that can accelerate reproducible single-cell analysis is available from Single Cell Portal under accession SCP2316 (https://singlecell.broadinstitute.org/single_cell/study/SCP2316). However, the raw data is not available due to patient privacy concerns. >>>Submitter states: The raw data is not available due to patient privacy concerns<<<